SEROFLO

Información principal

  • Denominación comercial:
  • SEROFLO 25 mcg-50 mcg/DOSIS SUSPENSI
  • Dosis:
  • 25 mcg-50 mcg
  • formulario farmacéutico:
  • SUSPENSI
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • CIPLA L.T.D.

Documentos

Localización

  • Disponible en:
  • SEROFLO 25 mcg-50 mcg/DOSIS SUSPENSI
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.35.262
  • Fecha de autorización:
  • 21-06-2006
  • última actualización:
  • 03-09-2018

Prospecto

31-5-2018

Fluticasone Propionate Nasal Spray by Apotex Corp: Recall - Due to Potential for Small Glass Particles

Fluticasone Propionate Nasal Spray by Apotex Corp: Recall - Due to Potential for Small Glass Particles

The glass particles could block the actuator and impact the functionality of the pump and expose patients to the glass particles.

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

6-11-2018

Trelegy Ellipta (GlaxoSmithKline Trading Services Limited)

Trelegy Ellipta (GlaxoSmithKline Trading Services Limited)

Trelegy Ellipta (Active substance: fluticasone furoate/umeclidinium/vilanterol) - Centralised - 2-Monthly update - Commission Decision (2018)7416 of Tue, 06 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4363/WS/1369

Europe -DG Health and Food Safety

6-11-2018

Elebrato Ellipta (GlaxoSmithKline Trading Services Limited)

Elebrato Ellipta (GlaxoSmithKline Trading Services Limited)

Elebrato Ellipta (Active substance: fluticasone furoate/umeclidinium/vilanterol) - Centralised - 2-Monthly update - Commission Decision (2018)7417 of Tue, 06 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4781/WS/1369

Europe -DG Health and Food Safety

3-7-2018

Revinty Ellipta (Glaxo Group Ltd)

Revinty Ellipta (Glaxo Group Ltd)

Revinty Ellipta (Active substance: fluticasone furoate / vilanterol) - Corrigendum - Commission Decision (2014)3040 of Tue, 03 Jul 2018

Europe -DG Health and Food Safety

3-7-2018

Relvar Ellipta (Glaxo Group Ltd)

Relvar Ellipta (Glaxo Group Ltd)

Relvar Ellipta (Active substance: fluticasone furoate/vilanterol) - Corrigendum - Commission Decision (2013)8089 of Tue, 03 Jul 2018

Europe -DG Health and Food Safety

3-5-2018

Avamys (Glaxo Group Ltd)

Avamys (Glaxo Group Ltd)

Avamys (Active substance: Fluticasone furoate) - Centralised - Yearly update - Commission Decision (2018)2773 of Thu, 03 May 2018

Europe -DG Health and Food Safety